Coherus Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus Biosciences, Inc. (CHRS) on December 7, 2023. The report discloses a material corporate governance event regarding the departure of a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change disclosed is the resignation of McDavid Stilwell as Chief Financial Officer (CFO) and Principal Financial Officer. His resignation is effective December 31, 2023, to pursue other opportunities. The company states there is no disagreement regarding operations, financial statements, internal controls, or policies.
Outlook and Management Commentary
Management notes that Mr. Stilwell may provide ongoing services beyond his effective resignation date by mutual agreement. No specific financial guidance, risk factors, or unusual items are detailed in this specific filing.
Investor Verification Checklist
- Verify the appointment of an interim or permanent successor to the CFO role.
- Confirm the terms of any ongoing service agreement with the departing CFO.
- Review subsequent filings for any impact on internal controls or financial reporting timelines.